Overdose Prevention Program
HB355 amends New Mexico’s Harm Reduction Act to create a new “overdose prevention program” within the Department of Health, alongside the existing harm reduction program. The department would be required to adopt rules for the new program by July 1, 2026, and begin administering it by January 1, 2027. The bill directs the department to qualify participants, issue participant identification, collect limited data, and report annually to the legislative health and human services committee. It also expands the advisory committee structure and requires the department to develop policies for evaluation, data collection, and rulemaking recommendations.
The bill broadens the services that may be offered through both programs. In addition to sterile syringes, testing supplies, education, and referrals to treatment, the overdose prevention program would provide a safe and hygienic space where trained personnel can monitor participants who consume previously obtained controlled substances and intervene in the event of an overdose. The bill also authorizes mobile overdose prevention services and co-location with other health care services, and it allows private providers certified for harm reduction services to participate in the new program after meeting additional requirements.
HB355 would amend Chapter 24, Article 2C NMSA 1978, expanding the state’s public health framework for drug-use harm reduction by formally creating an overdose prevention program and adding related rulemaking, reporting, and service-delivery requirements. It would also create broad civil and criminal liability protections for people and entities acting in good faith under the Harm Reduction Act, including program operators, employees, volunteers, participants, and property owners, and would limit the use of evidence, searches, nuisance claims, professional discipline, and certain immigration-related consequences tied to participation or operation of these programs. The bill would primarily affect the Department of Health, certified providers, participants, and property owners hosting program services.
The available context shows no recorded committee debate or votes, so there is no documented opposition or support in the provided materials. Based on the bill’s structure, the measure appears to be framed as a public health and overdose-response initiative, with a focus on reducing overdose deaths, disease transmission, and other negative outcomes associated with drug use. The inclusion of liability protections and safe-consumption-style services suggests the bill is designed to be protective and implementation-oriented rather than punitive.
The main likely points of contention are the creation of an overdose prevention program that includes a supervised space for consuming previously obtained controlled substances, and the broad immunity provisions shielding participants, operators, and property owners from criminal, civil, administrative, and certain immigration-related consequences. Critics may view these provisions as encouraging drug use or creating legal and public safety concerns, while supporters are likely to emphasize overdose reversal, disease prevention, and linkage to treatment. The bill also narrows data collection and limits law-enforcement-style consequences, which may raise concerns among public safety or enforcement stakeholders, although the advisory committee includes the Department of Justice and Department of Public Safety.